The 5 agents in ViPOR—including venetoclax and lenalidomide—worked better together in a phase 1b/2 trial than they previously have, individually, in treating patients with certain diffuse large B-cell ...
Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has ...
VIPorbit Software, makers of Vipor CRM for Apple's iPhone, iPad, and Mac, has updated its software with Apple Watch functionality and other performance enhancements. Available in both the iTunes and ...
Almost 40% of patients with relapsed/refractory lymphomas achieved complete responses (CRs) with a five-drug regimen that targeted different cancer-survival pathways, a preliminary clinical trial ...
Large B-cell lymphoma (LBCL) spans the gamut of aggressive lymphoid tumors with extensive biologic and clinical heterogeneity. Most patients with LBCL are cured with the use of front-line ...
Please provide your email address to receive an email when new articles are posted on . A novel multidrug regimen targeting survival pathways in diffuse large B-cell lymphoma produced significant ...
The team is also studying the ViPOR regimen in people with other types of lymphoma that are resistant to previous therapies. The researchers have developed a larger phase 2 study, which will be ...
Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has ...
NOTE: A virtual briefing is scheduled for Tuesday, June 18, 2024, at 1:00 p.m. ET. Details below. Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results